{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:21:22Z","timestamp":1790526082601,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00259-016-3437-y","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:02:10Z","timestamp":1466640130000},"page":"2122-2130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand"],"prefix":"10.1007","volume":"43","author":[{"given":"Stefano","family":"Boschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Beykan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Slavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Spick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Cicoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"3437_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339. doi: 10.1002\/jcb.10661 .","journal-title":"J Cell Biochem"},{"key":"3437_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397. doi: 10.1021\/bc200279b .","journal-title":"Bioconjug Chem"},{"key":"3437_CR3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med. 2015. doi: 10.2967\/jnumed.115.158550 .","journal-title":"J Nucl Med"},{"key":"3437_CR4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1568026611313080008","volume":"13","author":"RC Mease","year":"2013","unstructured":"Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951\u201362.","journal-title":"Curr Top Med Chem"},{"key":"3437_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.06.004","author":"R Schiavina","year":"2015","unstructured":"Schiavina R, Ceci F, Romagnoli D, et al. Ga-PSMA-PET\/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer. Clin Genitourin Cancer. 2015. doi: 10.1016\/j.clgc.2015.06.004 .","journal-title":"Clin Genitourin Cancer"},{"key":"3437_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.010","author":"L Budaus","year":"2015","unstructured":"Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2015. doi: 10.1016\/j.eururo.2015.06.010 .","journal-title":"Eur Urol"},{"key":"3437_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185\u201390. doi: 10.2967\/jnumed.115.160382 .","journal-title":"J Nucl Med"},{"key":"3437_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2967\/jnumed.115.157339","volume":"56","author":"H Jadvar","year":"2015","unstructured":"Jadvar H. PSMA PET, in prostate cancer. J Nucl Med. 2015;56:1131\u20132. doi: 10.2967\/jnumed.115.157339 .","journal-title":"J Nucl Med"},{"key":"3437_CR9","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","volume":"42","author":"F Ceci","year":"2015","unstructured":"Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284\u201394. doi: 10.1007\/s00259-015-3078-6 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3437_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374. doi: 10.2967\/jnumed.115.154153 .","journal-title":"J Nucl Med"},{"key":"3437_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, Demirci E, Ocak M, et al. Evaluation of PSMA PET\/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582\u20137. doi: 10.1097\/MNM.0000000000000290 .","journal-title":"Nucl Med Commun"},{"key":"3437_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/RLU.0000000000000709","volume":"40","author":"PS Chakraborty","year":"2015","unstructured":"Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET\/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015;40:328\u20139. doi: 10.1097\/RLU.0000000000000709 .","journal-title":"Clin Nucl Med"},{"key":"3437_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00117-014-2792-6","volume":"55","author":"M Avanesov","year":"2015","unstructured":"Avanesov M, Karul M, Derlin T. (68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence. Radiologe. 2015;55:89\u201391. doi: 10.1007\/s00117-014-2792-6 .","journal-title":"Radiologe"},{"key":"3437_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209. doi: 10.1007\/s00259-014-2949-6 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3437_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-014-2922-4","volume":"42","author":"C Uprimny","year":"2015","unstructured":"Uprimny C, Kroiss A, Nilica B, et al. (68)Ga-PSMA ligand PET versus (18)F-NaF PET: evaluation of response to (223)Ra therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging. 2015;42:362\u20133. doi: 10.1007\/s00259-014-2922-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3437_CR16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0969-8043(02)00123-9","volume":"57","author":"R Iwata","year":"2002","unstructured":"Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, Yanai K. [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine. Appl Radiat Isot. 2002;57:347\u201352.","journal-title":"Appl Radiat Isot"},{"key":"3437_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.nucmedbio.2014.12.019","volume":"42","author":"L Evangelista","year":"2015","unstructured":"Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L. (1)(8)F-fluoromethylcholine or (1)(8)F-fluoroethylcholine pet for prostate cancer imaging: which is better? a literature revision. Nucl Med Biol. 2015;42:340\u20138. doi: 10.1016\/j.nucmedbio.2014.12.019 .","journal-title":"Nucl Med Biol"},{"key":"3437_CR18","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645\u201353. doi: 10.1158\/1078-0432.CCR-11-1357 .","journal-title":"Clin Cancer Res"},{"key":"3437_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0844-6","author":"N Malik","year":"2015","unstructured":"Malik N, Baur B, Winter G, Reske SN, Beer AJ, Solbach C. Radiofluorination of PSMA-HBED via AlF chelation and biological evaluations in vitro. Mol Imaging Biol. 2015. doi: 10.1007\/s11307-015-0844-6 .","journal-title":"Mol Imaging Biol"},{"key":"3437_CR20","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","volume":"14","author":"RC Mease","year":"2008","unstructured":"Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036\u201343. doi: 10.1158\/1078-0432.CCR-07-1517 .","journal-title":"Clin Cancer Res"},{"key":"3437_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2191-219X-3-36","volume":"3","author":"WJ McBride","year":"2013","unstructured":"McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013;3:36. doi: 10.1186\/2191-219X-3-36 .","journal-title":"EJNMMI Res"},{"key":"3437_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/bc200608e","volume":"23","author":"WJ McBride","year":"2012","unstructured":"McBride WJ, D\u2019Souza CA, Karacay H, Sharkey RM, Goldenberg DM. New lyophilized kit for rapid radiofluorination of peptides. Bioconjug Chem. 2012;23:538\u201347. doi: 10.1021\/bc200608e .","journal-title":"Bioconjug Chem"},{"key":"3437_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1021\/bc200175c","volume":"22","author":"CA D\u2019Souza","year":"2011","unstructured":"D\u2019Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793\u2013803. doi: 10.1021\/bc200175c .","journal-title":"Bioconjug Chem"},{"key":"3437_CR24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1162\/153535003322556877","volume":"2","author":"AM Loening","year":"2003","unstructured":"Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131\u20137.","journal-title":"Mol Imaging"},{"key":"3437_CR25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1874471011306010004","volume":"6","author":"AH Repetto-Llamazares","year":"2013","unstructured":"Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr Radiopharm. 2013;6:20\u20137.","journal-title":"Curr Radiopharm"},{"key":"3437_CR26","unstructured":"Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. . In: Stelson A, Stabin M, Sparks R, editors. Sixth International Radiopharmaceutical Dosimetry Symposium 1999. p. 705\u201316."},{"key":"3437_CR27","first-page":"1","volume":"32","author":"International Commission on Radiological Protection (ICRP)","year":"2002","unstructured":"International Commission on Radiological Protection (ICRP). Publication 89: basic anatomical and physiological data for use in radiological protection\u2014reference values. Ann ICRP. 2002;32:1\u2013278.","journal-title":"Ann ICRP"},{"key":"3437_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1088\/0031-9155\/52\/4\/010","volume":"52","author":"A Bitar","year":"2007","unstructured":"Bitar A, Lisbona A, Thedrez P, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). Phys Med Biol. 2007;52:1013\u201325. doi: 10.1088\/0031-9155\/52\/4\/010 .","journal-title":"Phys Med Biol"},{"key":"3437_CR29","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1118\/1.4820367","volume":"40","author":"P Kletting","year":"2013","unstructured":"Kletting P, Schimmel S, Kestler HA, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40:102504. doi: 10.1118\/1.4820367 .","journal-title":"Med Phys"},{"key":"3437_CR30","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"3437_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0866-0","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [F]DCFPyL and [Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015. doi: 10.1007\/s11307-015-0866-0 .","journal-title":"Mol Imaging Biol"},{"key":"3437_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0850-8","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015. doi: 10.1007\/s11307-015-0850-8 .","journal-title":"Mol Imaging Biol"},{"key":"3437_CR33","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"3437_CR34","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1021\/acs.biomac.5b00913","volume":"16","author":"AV Fuchs","year":"2015","unstructured":"Fuchs AV, Tse BW, Pearce AK, et al. Evaluation of polymeric nanomedicines targeted to PSMA: effect of ligand on targeting efficiency. Biomacromolecules. 2015;16:3235\u201347. doi: 10.1021\/acs.biomac.5b00913 .","journal-title":"Biomacromolecules"},{"key":"3437_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1124\/jpet.110.174870","volume":"336","author":"ST Kochuparambil","year":"2011","unstructured":"Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011;336:496\u2013505. doi: 10.1124\/jpet.110.174870 .","journal-title":"J Pharmacol Exp Ther"},{"key":"3437_CR36","first-page":"1809","volume":"43","author":"JS Horoszewicz","year":"1983","unstructured":"Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809\u201318.","journal-title":"Cancer Res"},{"key":"3437_CR37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.161299","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015. doi: 10.2967\/jnumed.115.161299 .","journal-title":"J Nucl Med"},{"key":"3437_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320. doi: 10.1007\/s00259-013-2525-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3437_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3747\/pdi.2011.00203","volume":"32","author":"V Lavergne","year":"2012","unstructured":"Lavergne V, Ghannoum M, Christie M, et al. Risk factors and consequences of hyperaluminemia in a peritoneal dialysis cohort. Perit Dial Int. 2012;32:645\u201351. doi: 10.3747\/pdi.2011.00203 .","journal-title":"Perit Dial Int"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3437-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:32:27Z","timestamp":1526639547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3437-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3437-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,22]]}}}